Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies
Chronic myeloid leukemia (CML) / Posted 4 days ago
Part A ( for Healthy volunteers) of the study is completed
Part B dose-escalation study is completed. Recruitment in dose-expansion is ongoing in India and Korea
Part C study in subjects with treatment-refractory/intolerant is enrolling globally.